Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

Autor: Felipe Martinez, Lars Køber, Morten Schou, Pooja Dewan, Rudolf A. de Boer, John J.V. McMurray, Pardeep S. Jhund, Mikaela Sjöstrand, Olof Bengtsson, Masafumi Kitakaze, Piotr Ponikowski, Marc S. Sabatine, Daniel Lindholm, Scott D. Solomon, Anna Maria Langkilde, Kieran F. Docherty, Mikail N. Kosiborod, Subodh Verma, Nathaniel M. Hawkins, Akshay S. Desai, Béla Merkely, Mark C. Petrie, Silvio E. Inzucchi, Jarosław Drożdż

Publikováno v: European Journal of Heart Failure
Dewan, P, Docherty, K F, Bengtsson, O, Boer, R A, Desai, A S, Drozdz, J, Hawkins, N M, Inzucchi, S E, Kitakaze, M, Køber, L, Kosiborod, M N, Langkilde, A M, Lindholm, D, Martinez, F A, Merkely, B, Petrie, M C, Ponikowski, P, Sabatine, M S, Schou, M, Sjöstrand, M, Solomon, S D, Verma, S, Jhund, P S & Mcmurray, J J V 2021, ' Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease : an analysis of DAPA-HF ', European Journal of Heart Failure, vol. 23, no. 4, pp. 632-643 . https://doi.org/10.1002/ejhf.2083
European Journal of Heart Failure, 23(4):ejhf.2083, 632-643. Wiley

Aims Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under‐prescription of beta‐blocke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54219025a51c218ef0e4eef7cb0456ce
http://europepmc.org/articles/PMC8247863